Pactamycin Analog Synthesis via Gene Cluster Cloning
Solution Overview
Problem
The emergence of multidrug-resistant bacterial infections necessitates the development of new antibiotics with novel mechanisms of action, as existing antibiotics face challenges in effectively treating resistant strains, and pactamycin, despite its antibacterial and anti-tumor properties, is limited by high toxicity and complex chemical synthesis.
Innovation Solution
The molecular cloning and characterization of the pactamycin biosynthetic gene cluster from Streptomyces pactum, including 53 genes, enables the genetic manipulation and production of pactamycin and its analogs, facilitating the development of less toxic and more efficacious derivatives through genetic and biosynthetic methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pactamycin is used to treat bacterial infections and tumors, then therapeutic efficacy is improved, but toxicity increases
Solution Approach 1:
The patent applies local quality by introducing specific modifications at particular positions of the pactamycin molecule (positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100). These localized structural changes allow the molecule to maintain its antibacterial and anti-tumor activity while reducing its toxic effects on mammalian cells
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters at multiple positions of the pactamycin structure. By changing substituents at positions 1-100, the patent optimizes the balance between therapeutic efficacy and toxicity, creating analogs with improved safety profiles while maintaining biological activity
2Productivity
If chemical synthesis methods are used to produce pactamycin, then production is achieved, but synthesis complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex pactamycin molecule into modular structural units corresponding to specific positions (1-100). This modular approach allows for systematic synthesis and modification of different portions of the molecule independently, simplifying the overall synthesis process and enabling more efficient production
Solution Approach 2:
The patent employs preliminary action by pre-establishing the modular structural framework of pactamycin with defined positions 1-100. This pre-organized structure allows for more straightforward subsequent modifications and synthesis steps, reducing the overall complexity of production compared to de novo synthesis of the complete molecule
Data Source
AI summary
This disclosure describes the molecular cloning of a pactamycin biosynthetic gene cluster from Streptomyces pactum ATCC 27456, characterization of individual genes in the gene cluster and the proteins encoded thereby as well as uses thereof. The pactamycin gene cluster is located within an 86.35 kilobases genetic locus and includes 53 open reading frames, 26 of which are considered to be the core cluster directly involved in the biosynthesis of pactamycin. The present disclosure also relates to the use of the pactamycin biosynthetic genes located within the identified gene cluster for drug design and development purposes, including the development of pactamycin analogs that are more efficacious and less toxic. Also provided are drugs and antibiotics so produced, as well as methods of their use.